Abstract
The neurologic complications of cystathionine β-synthase deficiency are though to be secondary to accumulation of homocyst(e)ine in the CNS. Treatment of this disorder with betaine has been shown to improve the behavior of individuals, to reduce plasma total homocysteine, and to correct secondary abnormalities of serine. To test the hypothesis that homocyst(e)ine accumulates within the CNS and that this can be reduced by treatment with betaine, we measured total homocysteine and related metabolites in the plasma of 10 children with cystathionine β-synthase deficiency and cerebrospinal fluid of five children before and during betaine therapy. In plasma, betaine significantly lowered total homocysteine (but not to the normal range) and had a variable effect on methionine. In the cerebrospinal fluid, total homocysteine was raised before treatment (mean 1.2 μM) and was significantly reduced by betaine (mean 0.32 μM) but not to the normal range (<0.10 μM). Cerebrospinal fluid methionine was raised before and during treatment, but betaine did not cause a significant further increase. Cerebrospinal fluid serine was significantly reduced before treatment and rose to the normal range with betaine. Cerebrospinal fluid S-adenosylmethionine was normal before treatment and rose significantly with treatment; there were no significant changes in cerebrospinal fluid 5-methyltetrahydrofolate. The demonstration of accumulation of homocysteine within the CNS lends support to the hypothesis that this may be one cause of the neurologic complications of cystathionine β-synthase deficiency. Betaine is effective in reducing cerebrospinal fluid homocysteine, but concentrations are still significantly raised during treatment.
Similar content being viewed by others
Main
Homocystinuria due to cystathionine β-synthase (EC 4.2.1.22) deficiency is an inborn error of the transsulfuration and one-carbon transfer pathways (Fig. 1). It has ocular, skeletal, vascular, and neurologic complications(1). Biochemically the disorder is characterized by an increase in plasma concentrations of homocystine (and other mixed disulfides of homocysteine) and methionine, with homocystine in the urine. The cofactor for cystathionine β-synthase is pyridoxal phosphate, and approximately half of patients with homocystinuria respond to pharmacologic doses of pyridoxine. Pyridoxine non-responders are treated by a low methionine diet and/or the methyl-donor betaine. Betaine is a substrate for the enzyme betaine-homocysteine methyltransferase (EC 2.1.1.5) that catalyzes the remethylation of homocysteine to methionine. Betaine has previously been shown to reduce plasma concentrations of homocysteine(2–5) and to correct secondary abnormalities in plasma serine concentration(4,5).
The neurologic complications of cystathionine β-synthase deficiency include intellectual deficits, seizures, dystonia and other extrapyramidal motor disorders, rages and other psychiatric disturbances, and cerebrovascular events(6–10). The pathogenesis of these is not clear. Intellectual deficits occur in approximately 50% of cases, and although cerebrovascular disease has been suspected as the cause(1, 11, 12), the absence of focal clinical signs and the partial reversibility of the impairment in response to treatment suggest a metabolic basis(2, 3, 10, 13). There is little information about the metabolic changes in the CNS in cystathionine β-synthase deficiency, although homocystine has been found to be elevated in the cerebrospinal fluid of two untreated patients(1, 14). This suggests that homocysteine may accumulate within the CNS, and may be important in the pathogenesis of the neurologic complications.
To examine whether homocysteine accumulates within the CNS in cystathionine β-synthase deficiency, we have measured total homocysteine and related metabolites in the cerebrospinal fluid of five children before and during treatment with betaine. Because betaine-homocysteine methyltransferase is not present in the brain(15), any effect of betaine upon brain metabolites must be indirect by altering hepatic metabolism of homocysteine. We therefore also measured plasma concentrations of some metabolites in these patients and in five additional children with cystathionine β-synthase deficiency.
METHODS
Five patients were studied aged 6-14 y; each had pyridoxine-nonresponsive cystathionine β-synthase deficiency. The diagnosis was made by the clinical findings, demonstration of a raised methionine and homocyst(e)ine (either homocystine or total homocysteine) concentration in plasma, and the absence of a biochemical response to a trial of pyridoxine. Each child had a lumbar puncture during general anesthesia for eye surgery. Two patients were treated with a methionine-restricted diet and folic acid (10 mg daily) throughout the study, the others were untreated before they received betaine. Each patient was studied before and during treatment with betaine monohydrate (Fluka, Poole, UK) 250 mg/kg/d, the duration of treatment varied between 3 and 6 mo, and compliance was ensured by parental supervision. We also studied changes in plasma metabolites alone in five additional patients (nos. 6-10). Brief patient details are given in Table 1. Approval for the study was obtained from the Research Ethics Committee of the Institute of Child Health and Great Ormond Street Hospital for Children, London.
Cerebrospinal fluid was sampled before and during treatment with betaine, and the following metabolites were measured: total homocysteine, methionine, S-adenosylmethionine, serine, glycine, and 5-methyltetrahydrofolate. Cerebrospinal fluid was collected in a standardized manner(16) after a 4-h fast with the last dose of betaine given 12-16 h previously, frozen in liquid nitrogen at the bedside, and stored at -70 °C until analysis. All metabolites were measured on the third milliliter of cerebrospinal fluid. Plasma samples were taken before and during treatment with betaine, and the following metabolites were measured: total homocysteine, methionine, serine, and glycine. Blood was taken into iced lithium heparin tubes after a 4-h fast in all patients, samples were separated within 15 min, and the plasma was stored at -70 °C until analysis.
A reference population of 27 closely age-matched (0.4-12.5 y) patients was also studied. Each had a neurologic disease not expected to interfere with the transmethylation or transulfuration pathways (10 nonspecific learning difficulties, 8 congenital lactic acidosis, 5 epilepsy, 2 Miller-Fisher syndrome, 1 albinism, 1 benign neonatal hypotonia). Each had simultaneous plasma and cerebrospinal fluid samples taken for diagnostic purposes, and these were treated as above.
Plasma and cerebrospinal fluid total homocysteine were measured using HPLC with UV detection, modified from a previously published method(17). The assay was linear up to 1 mM with a recovery of 93%. The lower limit of detection using spiked cerebrospinal fluid and a signal-to-noise ratio of 3:1 was 0.1 μM. The within-day variation was 5%, and the between-day variation 9%. Plasma and cerebrospinal fluid methionine, serine, and glycine were measured using a Waters HPLC PicoTag system(18). Cerebrospinal fluid S-adenosylmethionine and 5-methyltetrahydrofolate were measured by HPLC with electrochemical detection as previously described(19, 20).
The results were grouped into those before betaine treatment, during treatment with betaine, and the reference range and analyzed by ANOVA after logarithmic transformation to equalize the variances. Post hoc significance testing used Tukey's HSD test; p values <0.05 were regarded as significant. Because of the relatively small number of cerebrospinal fluid samples, these results were also analyzed using nonparametric statistical methods. ANOVA by rank sum was performed with the Kruskal-Wallis test, and post hoc significance testing used an anolog of the Tukey test(21). Statistical analyses were performed using SPSS for Windows software.
RESULTS
The results for both plasma and cerebrospinal fluid are summarized in Tables 2 and 3, and the results for cerebrospinal fluid are shown in Figure 2. There was no difference in the findings using either parametric or nonparametric statistical methods, and the results using parametric methods are shown.
Cerebrospinal fluid. Cerebrospinal fluid total homocysteine was significantly raised above the reference range before and during treatment with betaine, but treatment caused a significant reduction. Cerebrospinal fluid methionine was also significantly raised before treatment, and although the mean rose during treatment with betaine, the increase was not statistically significant. However, treatment did cause a significant rise in the cerebrospinal fluid methionine to homocysteine ratio. Betaine treatment caused the cerebrospinal fluid S-adenosylmethionine concentration to increase significantly above the reference range. Cerebrospinal fluid serine was significantly depressed before treatment, but normalized with treatment. Cerebrospinal fluid glycine was also significantly reduced before treatment and fell further with treatment. Although the mean 5-methyltetrahydrofolate concentrations fell with betaine treatment, there were only three posttreatment values, and the results were not statistically significant.
Plasma. In all the patients the plasma total homocysteine was significantly raised above the reference range before treatment. Treatment with betaine caused a significant fall in homocysteine concentrations, but these remained significantly above the reference range. Plasma methionine was significantly raised above the reference range both before and during treatment with betaine; but there was no significant difference between treated and untreated concentrations. The plasma methionine to homocysteine ratio was significantly increased before and during betaine therapy, but although treatment further increased the ratio, this was not statistically significant. Although there was no significant difference in the plasma concentrations of serine nor glycine before or during treatment compared with the reference range, treatment significantly raised plasma serine concentrations and reduced glycine.
Two children (nos. 1 and 10) were treated for 1 mo with a higher dose of betaine (500 mg/kg/d), which did not cause a further decrease in plasma total homocysteine concentrations.
DISCUSSION
We were unable to detect homocysteine in cerebrospinal fluid from our reference population, indicating that the normal concentration is less than 100 nM. Two reference ranges for cerebrospinal fluid total homocysteine concentrations have recently been published and give conflicting results. One group found concentrations of 7-20 nM in six adult control subjects(22), supporting the findings here. However, reference values in nine adult control subjects have also been reported to range from 280 to 660 nM(23), values that fall into the range we found in cystathionine β-synthase-deficient children receiving betaine. These latter authors used a different HPLC methodology, described adult patients, and gave no details of the collection method and the subsequent handling of the cerebrospinal fluid. It is possible that these factors may explain the discrepancies.
In children with cystathionine β-synthase deficiency, our findings in plasma are similar to those previously reported(3, 5). Before betaine therapy, plasma total homocysteine and methionine were raised. Betaine significantly reduced total homocysteine, but did not significantly alter plasma methionine, although concentrations increased in six patients. The effect of betaine on plasma methionine concentrations has previously been shown to be variable(3), and the present findings do not alleviate earlier fears that methionine toxicity might limit its use, because high concentrations are observed in some patients(24). During betaine therapy, however, plasma total homocysteine concentrations remain significantly raised, and increasing the dose of betaine did not further reduce these in the two patients studied. Unlike previous reports, plasma serine was not significantly reduced before treatment, but betaine did cause a significant rise in serine concentrations and a reciprocal significant fall in glycine concentration. This suggested that betaine decreased the flux through folate-dependent remethylation pathways as previously reported(5). The decreased flux through folate-dependent remethylation pathways might be caused by decreased activity of homocysteine:5-methyltetrahydrofolate methyltransferase (EC 2.1.1.13; methionine synthase)(5). However, our findings in cerebrospinal fluid that betaine treatment is associated with a fall in 5-methyltetrahydrofolate and a significant increase in S-adenosylmethionine suggest that the mechanism might be due to the inhibition of 5,10-methylenetetrahydrofolate reductase (EC 1.5.1.20) by S-adenosylmethionine(25). Most of our patients were not receiving supplemental folic acid treatment, which could limit the flux through folate-dependent pathways, and this may explain why plasma serine concentrations were not significantly decreased before treatment(5).
Total homocysteine and related metabolite concentrations in the cerebrospinal fluid from patients with cystathionine β-synthase deficiency have not previously been described. We found that these, in general, replicated the findings in plasma. The exception was glycine, which was significantly reduced in cerebrospinal fluid before treatment and fell further with betaine therapy.
The primate brain normally contains the enzyme cystathionine β-synthase(26), and its deficiency would be expected to lead to an accumulation of homocysteine within the cells of the CNS. In other tissues, intracellular accumulation of homocysteine causes export of homocysteine into the extracellular space(27). In the CNS, cerebrospinal fluid is in continuity with the extracellular space, and accumulation of homocysteine in this fluid is likely to reflect accumulation within the brain. The mammalian brain does not contain the enzyme betaine-homocysteine methyltransferase(15). So the effect of betaine is most probably mediated through changes in the plasma homocysteine concentration. Because we found that cerebrospinal fluid homocysteine concentrations decreased with betaine treatment, it suggests that the reduction in plasma total homocysteine concentration caused by betaine is responsible for the decrease in cerebrospinal fluid total homocysteine concentration. It is possible that a reduction in plasma concentration of homocysteine facilitates the active removal of homocysteine from the brain, thereby reducing its accumulation in the cerebrospinal fluid.
Although accumulation of homocysteine within the CNS seems to be one likely pathogenic mechanism leading to neurologic damage, it is not clear how this is mediated. The enzyme S-adenosylhomocysteine hydrolase (EC 3.3.1.1), which catabolizes S-adenosylhomocysteine (Fig. 1) is reversible and has kinetics that favor S-adenosylhomocysteine formation(28). S-Adenosylhomocysteine is a potent inhibitor of biologic methylations, and the ratio of S-adenosylmethionine to S-adenosylhomocysteine concentration determines the rate of biologic methylation(29). Here we have shown that the accumulation of homocysteine in the CNS is greatly in excess to the accumulation of S-adenosylmethionine, and it is likely that a wide variety of biologic methylations are disturbed. Another potential mechanism might involve the oxidation of homocysteine to homocysteic acid, which is an excitotoxin that activates the glutamate N-methyl-D-aspartate receptor(30). N-Methyl-D-aspartate receptor activation can cause neuronal cell death and is a suggested mechanism for the pathogenesis of many neurologic disorders(31).
We also showed a reduction in cerebrospinal fluid concentrations of serine and glycine before treatment and a further reduction in glycine with betaine treatment. These amino acids are readily interconverted and enter into a large number of synthetic reactions via the single carbon pool. Recently, Jaeken et al.(32) described 3-phosphoglycerate dehydrogenase deficiency, which causes deficiency of serine and glycine within the CNS and a severe neurologic disorder; although the reductions in serine and glycine are greater than those observed here.
The findings that homocysteine accumulated in the CNS in children with cystathionine β-synthase deficiency, and serine and glycine are significantly reduced, lend support to a biochemical pathogenesis of the neurologic complications(9). Although betaine has been shown to improve patient well being, this is the first demonstration that it can reduce the accumulation of homocysteine within the CNS. But, like the findings in plasma, betaine does not reduce cerebrospinal fluid homocysteine to normal, and the long-term outcome of this treatment is not known.
References
Carson NAJ, Dent CE, Field CMB, Gaull GE 1965 Homocystinuria. Clinical and pathological review of ten cases. J Pediatr 66:565-583. J Pediatr 66: 565–583.
Smolin I.A, Benevenga NJ, Berlow S 1981 The use of betaine for the treatment of homocystinuria. J Pediatr 99: 467–472.
Wilcken DEL, Wilcken B, Dudman NPB, Tyrell PA 1983 Homocystinuria-the effects of betaine in the treatment of patients not responsive to pyridoxine. N Engl J Med 309: 448–453.
Wilcken DEL, Dudman NPB, Tyrell PA 1985 Homocystinuria due to cystathionine β-synthase deficiency-the effects of betaine treatment in pyridoxine-responsive patients. Metabolism 12: 1115–1121.
Dudman NPB, Tyrell PA, Wilcken DEL 1987 Homocysteinemia: depressed plasma serine levels. Metabolism 36: 198–201.
Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, Cerone R, Fowler B, Gröbe H, Schmidt H, Schweitzer L 1985 . The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 37: 1–31.
Kempster PA, Brenton DP, Gale AN, Stern GM 1988 Dystonia in homocystinuria. J Neurol Neurosurg Psychiatr 51: 859–862.
Berardelli A, Thompson PD, Zaccagnini M, Giardini O, D'Eufemia P, Massoud R, Manfredi M 1991 Two sisters with generalized dystonia associated with homocystinuria. Mov Disord 6: 163–165.
Mudd SH, Levy HL, Skovby F 1995 Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic and Molecular Bases of Inherited Disease, 7th Ed. McGraw-Hill, New York, pp 1279–1327.
Ludolph AC, Ullrich K, Bick U, Fathrendorf G, Przyrembel H 1991 Functional and morphological deficits in late-treated patients with homocystinuria: a clinical, electrophysiologic and MRI study. Acta Neurol Scand 83: 161–165.
Gibson JB, Carson NAJ, Neill DW 1964 Pathological findings in homocystinuria. J Clin Pathol 17: 427–437.
Perry TL 1974 Homocystinuria. In: Nyhan WL (Ed) Heritable Disorders of Amino Acid Metabolism. Wiley, New York, pp 395–428.
Gröbe H 1980 Homocystinuria (cystathionine synthase deficiency). Results of treatment in late diagnosed patients. Eur J Pediatr 135: 199–203.
Kennedy C, Shih VE, Rowland LP 1965 Homocystinuria: a report in two siblings. Pediatrics 36: 736–741.
McKeever MP, Weir DG, Malloy A, Scott JM 1991 Betaine-homocysteine methyltransferase: organ distribution in man, pig and rat and subcellular distribution in the rat. Clin Sci 81: 551–556.
Surtees R, Hyland K 1990 Cerebrospinal fluid concentrations of S-adenosylmethionine, methionine and 5-methyltetrahydrofolate in a reference population: cerebrospinal fluid S-adenosylmethionine declines with age in humans. Biochem Med Metab Biol 44: 192–199.
Refsum H, Helland S, Ueland PM 1985 Radioenzymatic determination of homocysteine in plasma and urine. Clin Chem 31: 624–628.
Davey JS, Erser RS 1990 Amino acid analysis of physiological fluids by high-performance liquid chromatography with phenylisothiocyanate derivatization and comparison with ion-exchange chromatography. J Chromatogr 528: 9–23.
Surtees R, Hyland K 1989 A method for the measurement of S-adenosylmethionine in small volume samples of cerebrospinal fluid or brain using high performance liquid chromatography-electrochemistry. Anal Biochem 181: 331–335.
Hyland K, Surtees R 1992 Measurement of 5-methyltetrahydrofolate in cerebrospinal fluid using HPLC with coulometric electrochemical detection. Pteridines 3: 149–150.
Zar JH 1984 Biostatistical Analysis, 2nd Ed. Prentice Hall, Englewood Cliffs, NJ, pp 199–202.
Blom HJ, Wevers RA, Verrips A, TePoele-Pothoff MTWB, Trijbels JMF 1993 Cerebrospinal fluid homocysteine and the cobalamin status of the brain. J Inherited Metab Dis 16: 517–519.
Hyland K, Bottiglieri T 1992 Measurement of total plasma and cerebrospinal fluid homocysteine by fluorescence following high-performance liquid chromatography and precolumn derivatization with o-phthaldialdehyde. J Chromatogr 579: 55–62.
Komrower GM, Sadharwalla IB 1971 The dietary treatment of homocystinuria. In Carson NAJ, Raine DN (eds) Inherited Disorders of Sulphur Metabolism. Churchill Livingstone, London, 254–263.
Kutzbach C, Stokstad ELR 1971 Mammalian methylenetetrahydrofolate reductase. Partial purification, properties and inhibition by S-adenosylmethionine. Biochim Biophys Acta 250: 459–477.
Rassin DK, Sturman JA, Gaull GE 1981 Sulfur amino acid metabolism in the developing rhesus brain: subcellular studies of the methylation cycle and cystathionine β-synthase. J Neurochem 36: 1263–1271.
Svardal A, Refsum H, Ueland PM 1986 Determination of in vivo protein binding of homocysteine and its relation to free homocysteine in the liver and other tissues of the rat. J Biol Chem 261: 3156–3163.
De la Haba G, Cantoni G 1959 The enzymatic synthesis of S-adenosyl-L-homocysteine from adenosine and homocysteine. J Biol Chem 234: 603–608.
Schatz RA, Wilens TE, Sellinger OZ 1981 Decreased transmethylation of biogenic amines after in vivo elevation of brain S-adenosyl-L-homocysteine. J Neurochem 36: 1739–1748.
Cuénod M, Audinat E, Do KQ, Gähwiler BH, Grandes P, Herrling P, Knöpfel T, Pershak H, Streit P, Vollenweider, Wieser HG 1990 Homocysteic acid as transmitter candidate in the mammalian brain and excitatory amino acids in epilepsy. Adv Exp Med Biol 268: 57–63.
Choi DW 1992 Excitotoxic cell death. J Neurobiol 23: 1261–1276.
Jaeken J, Detheux M, van Maldergem L, Foulon M, Carchon H, van Schaftingen E 1996 3-Phosphoglycerate dehydrogenase deficiency: an inborn error of serine biosynthesis. Arch Dis Child 74: 542–545.
Author information
Authors and Affiliations
Additional information
Supported by The Wellcome Trust (R.S. and A.B.).
Rights and permissions
About this article
Cite this article
Surtees, R., Leung, D., Bowron, A. et al. Cerebrospinal Fluid and Plasma Total Homocysteine and Related Metabolites in Children with Cystathionine β-Synthase Deficiency: The Effect of Treatment. Pediatr Res 42, 577–582 (1997). https://doi.org/10.1203/00006450-199711000-00004
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-199711000-00004
This article is cited by
-
Mechanisms of Toxic Effects of Homocysteine on the Nervous System
Neurophysiology (2019)
-
The sulfite molecule enhances homocysteine toxicity in SH-SY5Y cells
Molecular Biology Reports (2019)
-
Amino acid synthesis deficiencies
Journal of Inherited Metabolic Disease (2017)
-
A putative role for homocysteine in the pathophysiology of acute bacterial meningitis in children
BMC Clinical Pathology (2014)
-
An update on serine deficiency disorders
Journal of Inherited Metabolic Disease (2013)